- Home
- SSTK vs UPB Comparison
SSTK vs UPB Comparison
Compare SSTK & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- UPB
- Stock Information
- Founded
- SSTK 2003
- UPB 2021
- Country
- SSTK United States
- UPB United States
- Employees
- SSTK N/A
- UPB N/A
- Industry
- SSTK EDP Services
- UPB
- Sector
- SSTK Technology
- UPB
- Exchange
- SSTK Nasdaq
- UPB NYSE
- Market Cap
- SSTK 644.4M
- UPB 521.3M
- IPO Year
- SSTK 2012
- UPB 2024
- Fundamental
- Price
- SSTK $19.97
- UPB $11.20
- Analyst Decision
- SSTK Buy
- UPB Strong Buy
- Analyst Count
- SSTK 4
- UPB 4
- Target Price
- SSTK $43.67
- UPB $56.50
- AVG Volume (30 Days)
- SSTK 282.8K
- UPB 500.3K
- Earning Date
- SSTK 08-05-2025
- UPB 08-14-2025
- Dividend Yield
- SSTK 6.61%
- UPB N/A
- EPS Growth
- SSTK N/A
- UPB N/A
- EPS
- SSTK 1.09
- UPB N/A
- Revenue
- SSTK $963,567,000.00
- UPB $2,296,000.00
- Revenue This Year
- SSTK $11.31
- UPB N/A
- Revenue Next Year
- SSTK $2.40
- UPB N/A
- P/E Ratio
- SSTK $18.40
- UPB N/A
- Revenue Growth
- SSTK 10.30
- UPB N/A
- 52 Week Low
- SSTK $14.35
- UPB $5.14
- 52 Week High
- SSTK $46.10
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- SSTK 61.02
- UPB N/A
- Support Level
- SSTK $18.26
- UPB N/A
- Resistance Level
- SSTK $20.53
- UPB N/A
- Average True Range (ATR)
- SSTK 0.72
- UPB 0.00
- MACD
- SSTK 0.16
- UPB 0.00
- Stochastic Oscillator
- SSTK 79.33
- UPB 0.00
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.